Influence of curcumin supplementation on metabolic and lipid parameters of people living with HIV/AIDS: a randomized controlled trial

Background: Social support is an interpersonal relationship where the social environment provides assistance in the form of emotional attention, instrumental assistance, providing information, appreciation or assessment to individual sufferers. Lack of social support will lead to a decline in physical and mental conditions, so that it can cause a person to be lazy to carry out routine daily self-care activities, as a result people with HIV/AIDS do not adhere to treatment programs. If people with HIV/AIDS do not regularly take anti-retroviral (ARV) for a long time, it will greatly affect the quality of life of people with HIV/AIDS. This study aims to examine the effect of social support on quality of life in people with HIV/AIDS. Subject and Method: Meta analysis was conducted based on PRISMA guidelines on article with randomized controlled trial design which published in 2000-2020. The meta-analysis was carried out by systematically reviewing articles from Google Scholar, PubMed, and Springer Link. The articles used in this research are articles that have been published from 2010-2020. The keywords to find this article are as follows: “social support” AND “quality of life” OR “risk factor” AND “quality of life” OR “quality of life” AND “randomized controlled trial”. Articles are collected using the PRISMA diagram, and analyzed using the Review Manager 5.4 application. Results: There were 6 articles were reviewed in this study which met the criteria. Studies show that social support (OR = 3.14; 95% CI = 1.42 to 6.91; p <0.001) improves quality of life. Conclusion: Social support improves quality of life in people with HIV / AIDS. Keywords: social support, quality of life, people living with HIV / AIDS. Correspondence: Maria Regina Tri Yonita, Master Program in Public Health, Universitas Sebelas Maret, Jl. Ir. Sutami 36A, Surakarta 57126, Central Java, Indonesia. Email: [email protected]

Download Full-text

Computer-Based Counseling Program (CARE+ Kenya) to Promote Prevention and HIV Health for People Living With HIV/AIDS: A Randomized Controlled Trial

AIDS Education and Prevention ◽

10.1521/aeap.2019.31.5.395 ◽

2019 ◽

Vol 31 (5) ◽

pp. 395-406

Author(s):

Ann E. Kurth ◽

John E. Sidle ◽

Nok Chhun ◽

John A. Lizcano ◽

Stephen M. Macharia ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Risk Reduction ◽

Controlled Trial ◽

Hiv Treatment ◽

Transmission Risk ◽

People Living With Hiv ◽

Randomized Controlled ◽

Computer Based ◽

Living With Hiv ◽

Hiv Aids

In countries experiencing the dual burden of HIV disease and health care worker shortages, information and communication technology tools offer the potential to help support HIV treatment adherence and secondary HIV transmission risk reduction for people living with HIV/AIDS. We conducted a randomized controlled trial (September 1, 2011–July 12, 2012) with follow-up through April 2013. Participants were recruited from two clinics affiliated with the Academic Model Providing Access to Healthcare program in western Kenya. A total of 236 participants were enrolled, randomly assigned to intervention (n = 118) or risk-assessment only control (n = 118) and followed up for 9 months. Both arms had > 0.5 log10 reduction in viral load over time (p = .0007), a clinically relevant finding. A computer-based counseling tool is feasible and acceptable in a high-volume East African HIV setting and provides evidence-based ART adherence and risk reduction support that may extend health workforce deficits.

Download Full-text

Community Based Non Communicable Disease Services as a Predictor of Improved Quality of Life of People Living with HIV in Uganda: A Randomized Controlled Trial

Journal of Environmental Science and Public Health ◽

10.26502/jesph.96120102 ◽

2020 ◽

Vol 04 (04) ◽

Author(s):

Christopher Ddamulira ◽

Norman Nsereko ◽

Miph Musoke ◽

Frank Pio Kiyingi

Keyword(s):

Quality Of Life ◽

Randomized Controlled Trial ◽

Communicable Disease ◽

Controlled Trial ◽

People Living With Hiv ◽

Community Based ◽

Randomized Controlled ◽

Living With Hiv ◽

Non Communicable Disease

Download Full-text

A pilot randomized controlled trial of a tailored smoking cessation program for people living with HIV in the Washington, D.C. metropolitan area

BMC Research Notes ◽

10.1186/s13104-020-05417-3 ◽

2021 ◽

Vol 14 (1) ◽

Author(s):

Elexis C. Kierstead ◽

Emily Harvey ◽

Denisse Sanchez ◽

Kimberly Horn ◽

Lorien C. Abroms ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Smoking Cessation ◽

Self Efficacy ◽

Text Messaging ◽

Controlled Trial ◽

P Value ◽

People Living With Hiv ◽

Randomized Controlled ◽

Living With Hiv ◽

Pilot Randomized Controlled Trial

Abstract Objective Morbidity and mortality from smoking-related diseases among people living with HIV (PLWH) in the U.S. surpasses that due to HIV itself. Conventional smoking cessation treatments have not demonstrated strong efficacy among PLWH. We conducted a pilot randomized controlled trial (RCT) to evaluate a tailored smoking cessation intervention based on the minority stress model. We compared standard of care counseling (SOC) to a tailored intervention (TI) including one face-to-face counseling session incorporating cognitive behavioral therapy to build resilience, and 30 days of 2-way text messaging. Results The primary outcome was smoking cessation. Secondary outcomes included cigarettes per day (CPD), exhaled carbon monoxide (CO), and cessation self-efficacy. A total of 25 participants were enrolled (TI:11, SOC:14), and 2 were lost to follow-up. There were no significant differences in quit rates between study groups. However, there was a significantly greater decrease in CPD in the TI versus SOC (13.5 vs. 0.0, p-value:0.036). Additionally, self-efficacy increased in both groups (TI p-value:0.012, SOC p-value:0.049) and CO decreased in both groups (TI p-value: < 0.001, SOC p-value:0.049). This intervention shows promise to support smoking cessation among PLWH. A larger study is needed to fully evaluate the efficacy of this approach. Clinical trial: Trial Registration: Retrospectively registered (10/20/2020) NCT04594109.

Download Full-text